EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Phase 1a/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis

Henry W Nabeta, Maryam Zahin, Joshua L Fuqua, Elizabeth D Cash, Ingrid Leth, Michael Strauss, Jeanne Novak, Lin Wang, Angela Siegwald, Rachel A Sheppard, Shesh N Rai, Lisa C Rohan und 4 weitere

The University of Louisville Journal of Respiratory Infections · 17.11.2022 · 6 (1)

DOI: 10.55504/2473-2869.1250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The University of Louisville Journal of Respiratory Infections, online erschienen am 17.11.2022. Verfasst von Henry W Nabeta und 15 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID-19 pandemic remains an ongoing threat to global public health. Q-Griffithsin (Q-GRFT) is a lectin that has demonstrated potent broad-spectrum inhibitory activity in preclinical studies in models of Nipah virus and the beta coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2.

Methods

Here, we propose a clinical trial design to test the safety, pharmacokinetics (PK), and tolerability of intranasally administered Q-GRFT for the prevention of SARS-CoV-2 infection as a prophylaxis strategy. The initial Phase 1a study will assess the safety and PK of a single dose of intranasally administered Q-GRFT. If found safe, the safety, PK, and tolerability of multiple doses of intranasal Q-GRFT will be assessed in a Phase 1b study. Group 1 participants will receive 3 mg of intranasal Q-GRFT (200 μL/nostril) once daily for 7 days. If this dose is tolerated, participants will be enrolled in Group 2 to receive 3 mg twice daily for 7 days. Secondary endpoints of the study will be user perceptions, acceptability, and the impact of product use on participants’ olfactory sensation and quality of life.

Discussion

Results from this study will support further development of Q-GRFT as a prophylactic against respiratory viral infections in future clinical trials.

Zitieren

APA

Nabeta, H. W., Zahin, M., Fuqua, J. L., Cash, E. D., Leth, I., Strauss, M., Novak, J., Wang, L., Siegwald, A., Sheppard, R. A., Rai, S. N., Rohan, L. C., Hillier, S., Dryden, G. W., Potts, K. L., & Palmer, K. E. (2022). A Phase 1a/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis. The University of Louisville Journal of Respiratory Infections, 6(1). https://doi.org/10.55504/2473-2869.1250

Vancouver

Nabeta HW, Zahin M, Fuqua JL, Cash ED, Leth I, Strauss M, et al. A Phase 1a/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis. The University of Louisville Journal of Respiratory Infections. 2022;6(1). doi:10.55504/2473-2869.1250

BibTeX
@article{Nabeta2022,
  author = {Nabeta, Henry W and Zahin, Maryam and Fuqua, Joshua L and Cash, Elizabeth D and Leth, Ingrid and Strauss, Michael and Novak, Jeanne and Wang, Lin and Siegwald, Angela and Sheppard, Rachel A and Rai, Shesh N and Rohan, Lisa C and Hillier, Sharon and Dryden, Gerald W and Potts, Kevin L and Palmer, Kenneth E.},
  title = {A Phase 1a/1b Clinical Trial Design to Assess Safety, Acceptability, Pharmacokinetics and Tolerability of Intranasal Q-Griffithsin for COVID-19 Prophylaxis},
  journal = {The University of Louisville Journal of Respiratory Infections},
  year = {2022},
  volume = {6},
  number = {1},
  doi = {10.55504/2473-2869.1250}
}
Kostenlos starten →